A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
-
Published:2024-09
Issue:
Volume:
Page:
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Blay J.-Y.ORCID, Schiffler C., Bouché OlivierORCID, Brahmi Mehdi, Duffaud F., Toulmonde M.ORCID, Landi B., Lahlou W., Pannier D., Bompas E.ORCID, Bertucci F., Chaigneau L., Collard O., Pracht M., Henon C., Ray-Coquard I., Armoun K., Salas S., Spalato-Ceruso M., Adenis A., Verret B., Penel N., Moreau-Bachelard C., Italiano A., Dufresne A., Metzger S.ORCID, Chabaud S., Perol D., Le Cesne A.
Funder
INCa Commission européenne
Reference29 articles.
1. Gastrointestinal stromal tumours;Blay;Nat Rev Dis Primers,2021 2. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network;de Pinieux;PLoS One,2021 3. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial;DE Matteo;Ann Surg,2013 4. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up;Joensuu;JAMA Oncol,2020 5. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆
|
|